Early identification of pulmonary vascular disease remains a major unmet need in systemic sclerosis. In this context, the study by Kagami and colleagues provides important insights into the role of exercise stress echocardiography in detecting early hemodynamic abnormalities.
This webinar explores Group 3 pulmonary hypertension (PH) associated with COPD and ILD, including updated definitions, diagnosis, and treatment approaches.
Ten patients with post-COVID ILD-PH are described. This complication occurred only in patients after prolonged intensive care (ICU) admission for invasive mechanical ventilation.
Pregnancy in pulmonary arterial hypertension (PAH) is associated with substantial risks. Endothelin receptor antagonists (ERAs), including macitentan and bosentan, are contraindicated in pregnancy due to teratogenic effects observed in animal studies.
Invasive exercise hemodynamics are used to diagnose heart failure with preserved ejection fraction (HFpEF), based on pulmonary artery wedge pressure (PAWP) or left atrial (LA) pressure elevations.
Pretreatment with targeted pulmonary arterial hypertension (PAH) therapy in adults with unrepaired atrial septal defects (ASDs) has been increasingly reported as a means to improve pulmonary hemodynamics and expand candidacy for defect closure.
A dry powder inhaler (DPI) formulation of treprostinil was FDA-approved in March 2022 for patients with pulmonary arterial hypertension or pulmonary hypertension associated with ILD (PH-ILD).
Pulmonary hypertension is a known complication of scimitar syndrome; however, its risk factors and outcomes are not well understood. This study aimed to assess the prevalence, clinical features, risk factors, and outcomes of pulmonary hypertension in patients with scimitar syndrome.
Physical activity (PA) estimated by a wearable sensor may reflect clinical status in pediatric pulmonary hypertension (PH). Prior studies used research-grade hip-anchored sensors or commercial wrist sensors with proprietary scoring algorithms.
